SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...

Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX stock here.

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...

Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead ...

Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver ...

Brandi Jones has over two decades of experience as a nurse in an acute care setting. Her clinical background includes pediatrics, medical-surgical, and women's health. She also specializes in ...